News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
YA!!! THAT "FDA" SURE ARE A BUNCH OF JOKESTERS.
YIKES!!!!!!!!!!!!!!!!!!!!!!YIKES!!!!!!!!!!!!!!!!!!!!!!!YIKES!!!!!!!!!!!!!!!
BEAM ME UP, SCOTTY!!!!!!!!!!!!!!!!!!
There's nothing positive here.
I will definitely lose sleep because you don't care about my bs. That really hurts.
If the RS didn't pass, I would probably average down, but there's no way it stays at $1 or more for 10 days before November, so I know John will implement the RS. All he had to do was cancel the RS when he released the FDA approval PR... That's all it would have taken, but he has no functioning brain cells...
That would require brain cells. Sadly, nobody in the company has any as far as how to run a business.
|
Followers
|
193
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5553
|
|
Created
|
12/17/14
|
Type
|
Free
|
| Moderators INV4 Stockpile4u | |||
| This section maintained by INV4 Saving lives and improving healthcare by empowering clinicians to effectively treat patients faster At T2 Biosystems, our mission is to save lives and improve healthcare by empowering clinicians to get patients on the right therapy faster. We come to work every day to solve critical needs in healthcare diagnostics with innovative solutions built on our game-changing T2 Magnetic Resonance (T2MR®) detection technology. Sepsis claims more lives annually than breast cancer, prostate cancer, and AIDS combined. We’re focused on eradicating deaths due to sepsis by developing tools that help identify the most common and deadly sepsis-causing pathogens faster than ever before. Speed is critical in sepsis management. The faster patients receive effective treatment, the more likely they are to survive and have better outcomes. Better yet, early targeted therapy for bloodstream infections may prevent the progression to sepsis altogether. Our blood tests provide actionable results in just 3 to 5 hours. The only other way to identify the species-specific diagnosis requires a blood culture, which can take 1 to 5 days or more. Today, T2 Biosystems panels are getting patients on the right therapy faster, and the expedited identification of negative test results allows rapid de-escalation of unneeded therapy. In partnership with hospitals around the world, T2 Biosystems technology is uniquely positioned to strike a huge blow to sepsis and the hundreds of thousands of lives it takes each year. Our T2Bacteria® and T2Candida® Panels run on the automated T2Dx® Instrument. They are the first and only FDA-cleared blood tests that identify sepsis-causing pathogens without the wait for blood culture. As hospitals continue to adopt our technology, it will represent a paradigm shift that can potentially result in thousands of patients going home to their families instead of the tragic, and potentially avoidable, alternative. We have an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens About our name: T2 refers to the measurement of the reaction of water molecules in the presence of magnetic fields. This is what our T2MR technology measures, and it is the inspiration behind our company’s name. T2Dx Instrument Breakthrough technology enabling direct detection from whole blood The FDA-cleared T2Dx® Instrument is a fully automated, walk away, clinical multiplex benchtop diagnostic system capable of running tests directly from whole blood. The benefits of the T2Dx Instrument include
The T2Dx Instrument serves nearly 200 hospitals worldwide and is powered by T2 Magnetic Resonance (T2MR®) technology. ================================== Innovative T2MR®applications currently in development T2 Biosystems has multiple diagnostic applications in development, all designed to enable further breakthroughs in rapid and accurate therapy for patients. The diagnostics are focused on critical, unmet needs in healthcare, where solutions can serve a dual role of improving patient care while reducing costs. T2Resistance® Panel: T2 Biosystems has partnered with Allergan and CARB-X to develop panels with additional bacterial species and resistance markers. The T2Resistance Panel detects gram-negative and gram-positive resistance markers and is currently available for research use only (RUO) in the U.S. and CE marked on November 20, 2019. T2Cauris™ Panel RUO: Direct detection of the emerging superbug Candida auris in patient skin and blood samples and hospital environmental samples are now available for research use only (RUO) assays. The CDC* validated the T2Cauris Panel RUO swab test on patient skin samples and published their 2017 findings in Mycoses. 1. ANSON FUNDS MANAGEMENT LP Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise investment discretion, over the assets of others, in excess of $100 Million. Major institutions include financial holdings companies, banks, insurance companies, mutual fund managers, portfolio managers, self managed pension and endowment funds. The report is limited to equity securities, including common and equivalents, convertible preferred and convertible bonds. The report does not include fixed income, real estate, or cash equivalents. Reports are filed within 45 days after calendar quarter end with the vast majority of updates occurring near the 45th day of the quarter. About Institutional Holdings Institutional Holdings information can be used to gauge the volatility and value on the company’s stock. https://www.nasdaq.com/market-activity/stocks/ttoo/institutional-holdings Contact 101 Hartwell Avenue |
